ClinicalTrials.gg
Not yet recruitingNCT06466174CODECSUpdated Jun 20, 2024

Determination of the Safety and Efficacy of Two Probiotic Strains

An interventional study of Placebo 1 to Probiotic A and Probiotic A to Placebo 1 in Gastrointestinal Dysfunction, sponsored by The Archer-Daniels-Midland Company. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-20.

Sponsored by The Archer-Daniels-Midland Company · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this study is to determine the safety and efficacy of two probiotic strains in adults with mild to moderate gastrointestinal discomfort. The main questions it aims to answer is whether 6-week administration of a probiotic can improve how the participant feels regarding their gut health. This is done by completing a weekly questionnaire and the results are compared between the 6 weeks the participants are on a placebo and the 6 weeks the participants are on the probiotic. Participants will also provide a blood sample, and stool sample at the start and end of each treatment. Similarly, the results from the blood samples and stool samples will be analysed to determine if there is any improvement in markers related to gut health.

Read the detailed description

In this randomized, crossover, double-blind, prospective, placebo controlled study we aim to determine the safety and efficacy of two probiotic strains in adults with mild to moderate gastrointestinal discomfort. 100 healthy adults with subclinical mild to moderate gastrointestinal complaints (GSRS-IBS score 20-45 inclusive), 50 subjects per strain (test sequence). The GSRS-IBS (gastrointestinal symptom rating scale - irritable bowel syndrome) questionnaire ranges from 0-78 with a greater score indicating a higher occurrence of gastrointestinal symptoms. Safety: To evaluate adverse events that occur during the probiotic treatment period as compared to the placebo period. Incidence and duration of upper respiratory tract symptoms, urinary tract symptoms, gastrointestinal symptoms as primary outputs. Efficacy: To evaluate the effect of 6-week probiotic administration on gastrointestinal homeostasis using GSRS-IBS score as an index as compared to placebo. Following a screening period, participants will provide stool, urine (safety) and blood samples prior to commencing a 6 week course of either placebo or one of the probiotics. At this time participants will again provide blood and stool samples. Throughout the study participants will maintain a daily diary to note any unusual events and to report stool consistency using Bristol stool chart. The participants will also complete a once-weekly questionnaire (GSRS-IBS questionnaire) relating to gut health. There will then be a 3-week washout period where they will take no products. After these 3 weeks the participants will again provide a stool and blood samples, and as before maintain their daily diary and weekly questionnaire for 6 weeks while on the probiotic or placebo (they will have swapped at this point). After these 6 weeks the participants will again provide stool and blood samples.

02

Conditions studied

  • Gastrointestinal Dysfunction

Keywords

  • probiotic
  • gastrointestinal discomfort
03

In context

Lead sponsor

The Archer-Daniels-Midland Company is the lead sponsor of 19 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed form
  2. Healthy adults aged 18-65 years
  3. Subclinical mild to moderate gastrointestinal complaints (GSRS-IBS score 20-45 at baseline)

Exclusion criteria

Exclusion Criteria:

  1. Presence of a serious congenital anomaly or chronic medical condition that would contraindicate participation, including history of major gastrointestinal surgery, chronic gastrointestinal illness, abnormal intestinal anatomy or significant abdominal disorder
  2. Severe chronic illnesses
  3. Known immunodeficiency
  4. Use of agents (, methotrexate...)
  5. Presence of severe immunodeficient family members as provided by subjects self-report
  6. Pregnancy, 6 months postpartum period or current breastfeeding
  7. Women of childbearing age planning pregnancy during the course of the study
  8. Actively participating in another clinical study, having completed a clinical study in the past 60 days or being in the exclusion period of a previous clinical study
  9. Not able to understand and comply with requirements of the study
  10. Use of probiotics, prebiotics, postbiotics, antibiotics within 3 weeks of study commencement
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Placebo 1 to Probiotic A

    Sequence A1 (n=25): Placebo 1 administered daily for 42 days, followed by 21 days washout, then 1 x 10\^9 colony forming units (CFU) of Probiotic A administered daily for 42 days

    Dietary Supplement: Placebo 1 to Probiotic A

  • Active comparator
    Placebo 2 to Probiotic B

    Sequence B1 (n=25): Placebo 2 administered daily for 42 days, followed by 21 days washout and 42 days Probiotic formula: containing 1 x 10\^9 CFU of Probiotic B administered daily

    Dietary Supplement: Placebo 2 to Probiotic B

  • Active comparator
    Probiotic A to Placebo 1

    Sequence A2 (n=25): 1 x 10\^9 CFU of Probiotic A administered daily for 42 days, followed by 21 days washout, then Placebo 1 administered daily for 42 days

    Dietary Supplement: Probiotic A to Placebo 1

  • Active comparator
    Probiotic B to Placebo 2

    Sequence B2 (n=25): 1 x 10\^9 CFU of Probiotic B administered daily for 42 days, followed by 21 days washout and 42 days Placebo 2 administered daily for 42 days

    Dietary Supplement: Probiotic B to Placebo 2

Interventions

  • Dietary supplementPlacebo 1 to Probiotic A

    42 day Crossover study design between Placebo 1 and Probiotic A (n = 25)

  • Dietary supplementProbiotic A to Placebo 1

    42 day Crossover study design between Probiotic A and Placebo 1 (n = 25)

  • Dietary supplementPlacebo 2 to Probiotic B

    42 day Crossover study design between Placebo 2 and Probiotic B (n = 25)

  • Dietary supplementProbiotic B to Placebo 2

    42 day Crossover study design between Probiotic B and Placebo 2 (n = 25)

06

What researchers measure

Primary outcomes

  1. Change in GSRS-IBS score

    Change in the GSRS-IBS score while participants are on the treatment as compared with placebo. GSRS-IBS ranges from 0-78 with a greater score indicating a higher occurence of gastrointestinal symptoms

    Time frame: Baseline vs Week 6

Secondary outcomes

  1. Incidence of upper respiratory tract symptoms

    Incidence of upper respiratory tract symptoms, as captured by incidence of upper respiratory tract as reported by clinician/PI

    Time frame: Baseline vs Week 6

  2. Duration of upper respiratory tract symptoms

    Duration of upper respiratory tract symptoms, as captured by duration of upper respiratory tract as reported by clinician/PI

    Time frame: Baseline vs Week 6

  3. Incidence of urinary tract infections

    Incidence of urinary tract infections, as captured by incidence of urinary tract infections as reported by clinician/PI

    Time frame: Baseline vs Week 6

  4. Duration of urinary tract infections

    Duration of urinary tract infections, as captured by duration of urinary tract infections as reported by clinician/PI

    Time frame: Baseline vs Week 6

Other outcomes

  1. Change in Stool consistency

    To evaluate the difference in stool consistency as determined by daily Bristol stool chart scale captured in daily diary. The Bristol stool chart ranges from 1-7, with 1,2 being hard and solid and 6,7 being loose and watery. This readout will be the change in stool consistency towards types 3,4 and 5

    Time frame: Baseline vs Week 6

  2. Questionnaire regarding general health

    General health questionnaire regarding mood, sleep, energy, concentration and changes in appetite. This is based on a Likert scale ranging from 0 (no effect) to 7 (severe)

    Time frame: Baseline vs Week 6

  3. Changes in microbiome readouts

    To determine if there are any changes in alpha and beta diversity in the microbiome using 16S rRNA sequencing ( a common methodology used in assessing microbiome readouts) between placebo and probiotic treatment.

    Time frame: Baseline vs Week 6

  4. Changes in blood immune biomarkers

    To determine if there are any changes in biomarkers relating to immune markers including IL-6 (IL interleukin), IL-10, TNFalpha, IFNgamma in pg/mL serum.

    Time frame: Baseline vs Week 6

  5. Regularity of defecation

    Regularity of defecation as captured by daily diary

    Time frame: Baseline vs Week 6

  6. Changes in serum short chain fatty acid levels

    Changes in serum short chain fatty acids (SCFA's) including acetate, propionate and butyrate in micromol/L)

    Time frame: Baseline vs Week 6

  7. Changes in serum amino acids levels

    Changes in serum amino acids levels including the essential amino acids histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine; and the non-essential amino acids alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, proline, serine, and tyrosine in micromol/L

    Time frame: Baseline vs Week 6

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2024; primary completion for May 2026, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2024
First posted
Jun 20, 2024
StartEst.
Jun 2024
Primary completionEst.
May 2026
CompletionEst.
May 2026
Last update
Jun 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06466174
Lead sponsor
The Archer-Daniels-Midland Company
Collaborators
Merieux NutriSciences (China)
Responsible party
Sponsor
First posted
Jun 20, 2024
Start date
Jun 2024 (estimated)
Primary completion
May 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Jun 20, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion